Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Published 10 July 2009, doi:10.1136/bmj.b2489
Cite this as: BMJ 2009;339:b2489
D A Andreae, resident, paediatrics1, M H Andreae, consultant anaesthesiologist 2
1 St Josefskrankenhaus, Freiburg, Germany , 2 Vienna Medical University, Vienna
Correspondence to: D A Andreae adriana@andreae.org
| The first 150 words of the full text of this article appear below. |
Anaphylaxis is a serious allergic reaction that is rapid in onset and potentially fatal.1 Guidelines and experts agree that adrenaline (epinephrine) is the first line treatment for anaphylaxis.2 Internationally, however, treatment guidelines differ widely,3and the widespread use of antihistamines in anaphylaxis, often as first line treatment instead of adrenaline, has led to concern.4 5
No randomised controlled clinical trials or observational studies exist to inform us: a Cochrane review recently failed to identify any randomised controlled clinical trials evaluating antihistamines in acute anaphylaxis6; only one prospective trial was identified but was excluded as it lacked a control group and did not study patients with anaphylaxis.7 Our own PubMed search also did not identify any randomised controlled clinical trials or observational or cohort studies examining the appropriateness of antihistamines in anaphylaxis.
Unsurprisingly, a recent comparison of important international guidelines found conflicting advice about antihistamines,3 reflecting the uncertainty in international clinical
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
StumbleUpon
Technorati What's this?
Read all Rapid Responses